Patents by Inventor Ann Kwong

Ann Kwong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hepatitis C virus variants
    Patent number: 8501450
    Abstract: The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: August 6, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Chao Lin, Tara Kieffer, Christoph Sarrazin, Ann Kwong
  • COMPOSITIONS AND METHODS USEFUL FOR HCV INFECTION
    Publication number: 20130071834
    Abstract: The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.
    Type: Application
    Filed: June 29, 2012
    Publication date: March 21, 2013
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Ann Kwong, Randal Byrn, Lola M. Reid
  • COMBINATION THERAPY FOR THE TREATMENT OF HCV INFECTION
    Publication number: 20120295843
    Abstract: The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention.
    Type: Application
    Filed: August 1, 2012
    Publication date: November 22, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Ann Kwong, Nagraj Mani, Yi Zhou, Chao Lin
  • Combination therapy for the treatment of HCV infection
    Patent number: 8258116
    Abstract: The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: September 4, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Ann Kwong, Nagraj Mani, Yi Zhou, Chao Lin
  • Method useful for HCV RNA898 infection
    Patent number: 8211696
    Abstract: The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: July 3, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Ann Kwong, Randal Byrn, Lola M. Reid
  • HEPATITIS C VIRUS VARIANTS
    Publication number: 20110244549
    Abstract: The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
    Type: Application
    Filed: March 5, 2010
    Publication date: October 6, 2011
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Chao Lin, Tara Kieffer, Christoph Sarrazin, Ann Kwong
  • COMPOSITIONS AND METHODS USEFUL FOR HCV INFECTION
    Publication number: 20110229874
    Abstract: The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.
    Type: Application
    Filed: January 25, 2011
    Publication date: September 22, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Ann Kwong, Randal Byrn, Lola M. Reid
  • Compositions and methods useful for HCV infection
    Patent number: 7879606
    Abstract: The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: February 1, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Ann Kwong, Randal Byrn, Lola M Reid
  • Combination Therapy for the Treatment of HCV Infection
    Publication number: 20100172866
    Abstract: The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention.
    Type: Application
    Filed: May 5, 2008
    Publication date: July 8, 2010
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Ann Kwong, Nagraj Mani, Yi Zhou, Chao Lin
  • Hepatitis C virus variants
    Patent number: 7705138
    Abstract: The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: April 27, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Chao Lin, Tara Kieffer, Christoph Sarrazin, Ann Kwong
  • Hepatitis C virus variants
    Publication number: 20070231262
    Abstract: The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
    Type: Application
    Filed: November 13, 2006
    Publication date: October 4, 2007
    Inventors: Chao Lin, Tara Kieffer, Christoph Sarrazin, Ann Kwong
  • Animal model for HCV infection
    Publication number: 20050120398
    Abstract: The present invention relates to a non-transgenic, non-human animal useful as a model for protease activity and for liver damage, including steatosis.
    Type: Application
    Filed: September 13, 2004
    Publication date: June 2, 2005
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Gururaj Kalkeri, Ann Kwong
  • Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
    Publication number: 20030083467
    Abstract: The present invention relates to novel fusion proteins, DNA molecules encoding the same, vectors comprising the DNA molecules, and host cells containing the vectors for use in measuring protease activity using a novel transcriptional assay. This invention also relates to a method for determining the inhibitory activity of a compound against a protease and to a method for comparing the activity of two proteases which recognize the same cleavage site. Kits for assaying protease activity comprising DNA molecules encoding the fusion protein substrates of this invention are also contemplated.
    Type: Application
    Filed: November 20, 2002
    Publication date: May 1, 2003
    Inventors: Ursula Germann, Thomas Hoock, Ann Kwong
  • Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
    Patent number: 6528276
    Abstract: The present invention relates to novel fusion proteins, DNA molecules encoding the same, vectors comprising the DNA molecules, and host cells containing the vectors for use in measuring protease activity using a novel transcriptional assay. This invention also relates to a method for determining the inhibitory activity of a compound against a protease and to a method for comparing the activity of two proteases which recognize the same cleavage site. Kits for assaying protease activity comprising DNA molecules encoding the fusion protein substrates of this invention are also contemplated.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: March 4, 2003
    Assignee: Vertex Pharmaceuticals Inc.
    Inventors: Ursula Germann, Thomas Hoock, Ann Kwong
  • Compositions and methods useful for HCV infection
    Publication number: 20020142449
    Abstract: The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.
    Type: Application
    Filed: March 27, 2002
    Publication date: October 3, 2002
    Inventors: Ann Kwong, Randal Byrn, Lola M. Reid
  • Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
    Patent number: 6117639
    Abstract: The present invention relates to novel fusion proteins, DNA molecules encoding the same, vectors comprising the DNA molecules, and host cells containing the vectors for use in measuring protease activity using a novel transcriptional assay. This invention also relates to a method for determining the inhibitory activity of a compound against a protease and to a method for comparing the activity of two proteases which recognize the same cleavage site. Kits for assaying protease activity comprising DNA molecules encoding the fusion protein substrates of this invention are also contemplated.
    Type: Grant
    Filed: August 31, 1998
    Date of Patent: September 12, 2000
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Ursula Germann, Thomas Hoock, Ann Kwong